- Lonza posted CHF 3.6 billion in sales and CHF 1.1 billion CORE EBITDA in H1 2025, with 19.0% CER growth.
- CDMO business grew 23.1% CER, supported by the Vacaville site, mammalian demand, and strong execution.
Lonza has reported half-year (H1) 2025 results with sales reaching CHF 3.6 billion, representing 19.0% growth at constant exchange rates (CER). The company delivered a CORE EBITDA of CHF 1.1 billion, translating to a margin of 29.6%, up 0.4 percentage points from H1 2024.
The contract manufacturing segment, including the contribution from the newly acquired Vacaville site in the US, achieved 23.1% CER sales growth and a stable CORE EBITDA margin of 30.2%. Growth was led by momentum across Mammalian, Bioconjugates, and Small Molecules platforms, while Bioscience returned to healthy growth. Cell & Gene Technologies and Microbial saw softer performance due to high prior-year comparables and second-half-weighted delivery in 2025.
In Q1, Lonza began operations at its new highly potent API facility in Visp (CH) and commenced GMP operations at its large-scale mammalian drug substance plant in the same location by end of H1. Capital investment is also underway to upgrade automation and flexibility at the Vacaville site. Its commercial-scale aseptic drug product facility in Stein (CH) remains on track for 2027.
Looking ahead, Lonza has revised its full-year 2025 CDMO guidance to 20–21% CER sales growth, up from “approaching 20%,” with a CORE EBITDA margin of 30–31%. Excluding Vacaville, organic CDMO growth is forecast in the low teens. The company expects stronger H2 sales and margin stability, while closely monitoring macroeconomic and regulatory shifts, particularly in CGT.
CEO Wolfgang Wienand stated, “The performance of One Lonza in the first half of 2025 is built on our position as a preferred CDMO partner for the biopharmaceutical industry and our ability to deliver at or above the commitments made to our customers.”
The Capsules & Health Ingredients (CHI) business delivered flat sales with an improved 26.2% margin, and Lonza confirmed plans to exit the CHI segment. Despite ongoing FX headwinds, the company projects minimal margin impact due to hedging strategies.
